Plasma-derived product · Protein replacement · developed by Takeda Pharmaceuticals America
Anti-Inhibitor Coagulant Complex (FEIBA) is a plasma-derived concentrate of non-activated factors II, IX and X and mainly activated factor VII. These components interact with plasma coagulation factors and platelets to increase thrombin generation. It is used in hemophilia patients with inhibitors to factor VIII or factor IX, for bleeding control, perioperative management and routine prophylaxis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 27, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04563520 | Phase 3 | Hemophilia A | Withdrawn | TAK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hemophilia A
Updated Nov 15, 2026. Something wrong or missing? Report it on the TAK page.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →